Treatment of Advanced Gastric Cancer: Where We Are in 2003

نویسندگان
چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Reflection for the undergraduate on writing in the portfolio: where are we now and where are we going?

Introduction: The portfolio can be seen as a tool for assessmentof a variety of learning activities that differ in content, usage, andassessment. The portfolio not only meets the learner’s educationalneeds but also the political and public reassurance demand thatthe health professional has achieved the required competency ofthe curriculum that allows him or her to practice safely with orwithout...

متن کامل

Rheumatoid arthritis in 2003: where are we now with treatment?

The treatment of rheumatoid arthritis (RA) has changed considerably over the course of the century. It is difficult to fathom that 100 years ago it was directed towards removing potential sources of infection, with dental extractions and tonsillectomies. Despite appreciable advances, many of the tenets that we currently hold for the management of RA were originally proposed over 70 years ago. R...

متن کامل

Familial pancreatic cancer: where are we in 2003?

There is a sense of déjà vu for those of us involved in pancreatic cancer research. Many of us have had the opportunity to witness the buildup leading to spectacular discoveries of major genes in studies of hereditary colorectal cancer and breast cancer families. In the same way, we are tackling pancreatic cancer through the use of high-risk pedigrees, a task that is much more difficult with a ...

متن کامل

Second-Line Treatment of Advanced Gastric Cancer: Where Do We Stand?

Gastric cancer is a leading cause of cancer death and is associated with poor prognosis. The treatment of advanced gastric cancer is changing with the development of novel agents. Until recently, no standard treatment was available for patients with advanced gastric cancer in the second-line setting. Single-agent chemotherapy with docetaxel or irinotecan has been shown to improve survival and q...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Oncology Research and Treatment

سال: 2003

ISSN: 2296-5270,2296-5262

DOI: 10.1159/000071614